RxDoctor Payments Data

Lauren Gifford, APRN

Family · Bedford, NHNPI 1366841819

Payments from drug & device makers

$864in general payments, 2019–2025

Across 25 payments — averaging $34.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$268
  • AbbVie$146
  • Si-bone, Inc.$130
  • Painteq LLC$98
  • Radius Health, Inc.$70
  • Johnson & Johnson$50
  • plus $103 from 3 others

What the payments were for

  • Food & beverage$864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen10$268
AbbVie(2 entities)5$146
Si-bone, Inc.1$130
Painteq LLC1$98
Radius Health, Inc.4$70
Johnson & Johnson1$50
Novo Nordisk1$47
Abbott1$38
Nevro Corp.1$19

How this compares

$864 in reported general payments places this provider in the 80th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire

Medicare billing

Part B allowed, 2024
$33,965
Medicare patients
189
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide20$16,497
XareltoRivaroxaban16$16,416
OzempicSemaglutide15$14,361
EliquisApixaban13$9,427
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,131
Fluticasone-SalmeterolFluticasone Propion/Salmeterol20$2,626
Estradiol11$1,493
Atorvastatin Calcium185$1,314
SynthroidLevothyroxine Sodium14$945
Olmesartan Medoxomil37$811
Amlodipine Besylate111$742
Lisinopril137$696
Albuterol Sulfate HfaAlbuterol Sulfate34$638
Simvastatin47$592
Lorazepam61$541

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$50$16,41616 claims
Novo NordiskOzempic$47$14,36115 claims
AbbVieSynthroid$146$94514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 713 family providers in New Hampshire.

Other family in Bedford

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →